A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.
The first-in-class bispecific antibody mosunetuzumab-axgb (Lunsumio) has been granted an accelerated approval for use in relapsed or refractory follicular lymphoma.
The investigational monoclonal antibody showed impressive activity in patients with follicular lymphoma that had relapsed or was refractory to a median of 3 prior lines of therapy.